[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhongming Qiu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":230},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,42,63,93,117,137,159,181,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100621606","phase-1-ripertamab-for-the-treatment-of-myasthenia-gravis-100621606",false,"NCT07372807","Ripertamab for the Treatment of Myasthenia Gravis","Safety and Efficacy of Ripertamab in Generalized Myasthenia Gravis","RIPERT-MG","Inclusion Criteria:\n\n(1) Aged ≥ 18 years and ≤ 75 years at screening.(2) Confirmed diagnosis of generalized myasthenia gravis (gMG).(3) Positive for anti-acetylcholine receptor (anti-AChR), anti-muscle-specific kinase (anti-MuSK), and\u002For anti-low-density lipoprotein receptor-related protein 4 (anti-LRP4) antibodies.(4) A score of ≥ 6 on the Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale, with the ocular subscore accounting for less than 50% of the total score.(5) Classified as Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Types Ⅱ, Ⅲ, or Ⅳ.(6) Voluntary signing of the informed consent form by the patient and\u002For their legal representative.\n\nExclusion Criteria:\n\n(1) Any condition that the investigator deems likely to interfere with the evaluation of the study drug, assessment of patient safety, or interpretation of study results.(2) A history of any uncontrolled active infection or severe infection within 8 weeks prior to screening.(3) Receipt of rituximab or any B-cell depleting agent within 6 months prior to screening; note: Subjects with CD19+ or CD20+ B-cell counts above the lower limit of normal are eligible for enrollment.(4) Administration of tocilizumab, eculizumab, mitoxantrone, cyclophosphamide, or other alkylating agents within 3 months prior to the first dose.(5) Administration of immunosuppressants other than glucocorticoids within 1 month prior to the first dose, including but not limited to azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine, and methotrexate.(6) Receipt of plasma exchange (PE), moderate-volume blood transfusion, or immunomodulatory drugs (e.g., interferon β, interferon γ, or intravenous immunoglobulin \\[IVIG\\]) within 1 month prior to the first dose.(7) Performance of thymectomy within 12 months prior to baseline, or a planned thymectomy during the 12-week study period.(8) Comorbidity with other chronic active autoimmune diseases requiring treatment with glucocorticoids, biologics, or immunosuppressants (e.g., rheumatoid arthritis, scleroderma).(9) Vaccination with live or attenuated vaccines within 1 month prior to the first dose.(10) A history of previous bone marrow transplantation, hematopoietic stem cell transplantation, total lymphoid irradiation, or T-cell vaccine therapy.(11) Receipt of any investigational drug within 28 days prior to the first dose or 5 times the half-life of the investigational drug, whichever is shorter.(12) Known hypersensitivity to any component of ripertamab.(13) Pregnant or lactating females; for women of childbearing potential (WOCBP) who have not undergone sterilization: refusal to use appropriate contraceptive methods (e.g., oral contraceptives, intrauterine devices \\[IUDs\\], or barrier contraception combined with spermicides) from screening until 6 months after the end of treatment.(14) For males who have not undergone sterilization: refusal to use barrier contraception from screening until 6 months after the end of treatment, and refusal to request their partners to use other contraceptive methods (e.g., oral contraceptives, IUDs, barrier methods, or spermicides).","ALL","18 Years","75 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The goal of this clinical trial is to learn if ripertamab works to treat myasthenia gravis. It will also learn about the safety of ripertamab. The main questions it aims to answer are:Will ripertamab improve the symptoms of participants?What medical problems do participants have when using ripertamab?Researchers will compare ripertamab to a placebo (a look-alike substance that contains no drug) to see if ripertamab works to treat chronic inflammatory demyelinating polyneuropathy.Participants will:A single intravenous infusion of ripertamab.Visit the clinic for checkups and tests during W1, W2, W4, W8, W12. Keep a diary of their symptoms and the number of times they undergo rescue therapy.",[29],"Myasthenia Gravis (MG)","NOT_YET_RECRUITING","2026-01-19",{"date":33,"type":34},"2026-01-28","ACTUAL",{"date":36,"type":22},"2026-02",{"date":38,"type":22},"2027-12",{"name":40,"class":41},"Zhongming Qiu","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":4},"100620256","phase-2-telitacicept-in-inflammatory-myopathiestelitacicept-im-100620256","NCT07355257","TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)","Safety and Efficacy of Telitacicept in Inflammatory Myopathies","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 70 years.\n* Patient has a confirmed diagnosis of inflammatory myopathy, meeting the 2017 European League Against Rheumatism\u002FAmerican College of Rheumatology (EULAR\u002FACR) classification criteria for idiopathic inflammatory myopathies.\n* Inadequate response or intolerance to glucocorticoids and\u002For at least one immunosuppressant.\n* The patient or their legal guardian provides written informed consent.\n\nExclusion Criteria:\n\n* Female patients who are pregnant, breastfeeding, or planning a pregnancy during the trial period.\n* Patients with active infections, such as herpes zoster, HIV, active tuberculosis, active hepatitis, HBsAg-positive patients, or HCV antibody-positive patients.\n* Patients with positive test results indicating COVID-19 infection within 1 month prior to baseline.\n* Patients with a history of or currently diagnosed malignancy.\n* Patients with significant cardiovascular diseases (including severe arrhythmia), hepatic, renal, respiratory, endocrine, or hematological disorders, or any other medical condition that, in the investigator's judgment, would interfere with participation in the study or require hospitalization during the trial.\n* Patients who have received intravenous immunoglobulin (IVIG) or plasmapheresis within 1 month prior to baseline.\n* Patients who have received other targeted biologic therapies, such as rituximab, eculizumab, tocilizumab, etc., within 3 months prior to baseline.\n* Patients who have received any live vaccine within 3 months prior to baseline or plan to receive any vaccine during the study period.\n* Patients with a known allergy to human-derived biologics.\n* Patients currently participating in another clinical trial.\n* Patients deemed unsuitable for participation by the investigator for other reasons (e.g., severe psychiatric disorders).",{"count":50,"type":22},30,[26,52],"PHASE3","The goal of this clinical trial is to evaluate the efficacy of Telitacicept in the treatment of inflammatory myopathy in patients with inflammatory diseases. The main question it aims to answer is: the safety and effectiveness of Telitacicept in treating inflammatory myopathy.",[55],"Inflammatory Myopathy",{"date":57,"type":34},"2026-01-21",{"date":59,"type":22},"2026-02-02",{"date":61,"type":22},"2027-03-30",{"name":40,"class":41},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":71,"targetDuration":73,"studyType":74,"phases":4,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100532271","prospective-registry-of-endovascular-thrombectomy-for-extra-large-ischemic-stroke-100532271","NCT06210633","Prospective Registry of Endovascular Thrombectomy for eXtra-Large Ischemic Stroke","XL STROKE: A Nationwide Prospective Registry of Endovascular Thrombectomy for Extra-large Ischemic Stroke With Large Vessel Occlusion","XL-STROKE","Inclusion Criteria:\n\nClinical inclusion criteria\n\n1. Age ≥18 years;\n2. Presenting with acute ischemic stroke within 24 hours of time from last known well;\n3. The patient or patient's representative signs a written informed consent form before enrollment.\n\nNeuroimaging inclusion criteria\n\n1. Occlusion of internal carotid artery, or the middle cerebral artery M1 or M2 segments confirmed by computed tomography angiography, magnetic resonance angiography, or digital subtraction angiography;\n2. The baseline ASPECTS is 0 to 2 based on NCCT or diffusion weighted imaging, or cerebral extra-large ischemic core volume ≥85ml (defined as relative cerebral blood flow \\\u003C30% on CT perfusion or an apparent diffusion coefficient \\\u003C620×10\\^-6 mm2\u002Fs on MRI).\n\nExclusion criteria\n\n1. CT or MRI evidence of acute intracranial hemorrhage;\n2. Evidence of mass effect with ventricular effacement, midline shift or herniation on baseline imaging;\n3. Females who are pregnant, or those of childbearing, potential with positive urine or serum beta Human Chorionic Gonadotropin test;\n4. Previous bleeding disorders, severe heart, liver or kidney disease, or sepsis;\n5. Any terminal illness with life expectancy less than 6 months;\n6. Participation in other clinical treatment trials.",{"count":72,"type":22},1000,"3 Months","OBSERVATIONAL","Since 2015, many randomized trials have shown that endovascular thrombectomy improve functional outcomes in acute ischemic stroke patients with large vessel occlusion. Recently, five randomized controlled trials (ANGEL-ASPECT \\[Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients with a Large Infarct Core\\], LASTE \\[LArge Stroke Therapy Evaluation\\], RESCUE-Japan LIMIT \\[The Recovery by Endovascular Salvage for Cerebral Ultra-Acute Embolism-Japan Large Ischemic Core Trial\\], SELECT 2 \\[Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke\\], and TENSION \\[The Efficacy and Safety of Thrombectomy in Stroke with extended lesion and extended time window\\]) demonstrated the efficacy and safety of thrombectomy for large infarct patients (defined as Alberta Stroke Program Early Computed Tomography Score \\[ASPECTS\\] ≥3 or infarct core \\\u003C100ml). Patients with extra-large infarct core (ASPECTS score of 2 or less) were excluded from these trials. Therefore, the efficacy of endovascular thrombectomy in patients with extra-large ischemic burden has not been well studied. The XL STROKE registry is aiming to investigate the clinical outcomes and safety of mechanical thrombectomy in acute extra-large ischemic stroke.",[77,78],"Acute Ischemic Stroke (AIS)","Acute Ischemic Stroke From Large Vessel Occlusion",[80,81,82],"Acute ischemic stroke","large vessel occlusion","endovascular thrombectomy","RECRUITING","2025-12-24",{"date":86,"type":34},"2025-12-31",{"date":88,"type":34},"2024-01-20",{"date":90,"type":22},"2026-03-31",{"name":40,"class":41},1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100545916","endovascular-treatment-for-extra-large-ischemic-stroke-100545916","NCT06388148","Endovascular Treatment for eXtra-Large Ischemic Stroke","Efficacy and Safety of Endovascular Thrombectomy Plus Medical Management Versus Medical Management Alone in Acute Ischemic Stroke Patients With Large Vessel Occlusion and Extra-Large Infarct Core: A Multicenter, Randomized Controlled Trial","XL STROKE-2","Inclusion Criteria:\n\n1. Age 18 years or older, and modified Rankin scale score = 0 or 1 in patients 80 years or older;\n2. Acute ischemic stroke within 6 hours from last known well to randomization, or with negative MRI-FLAIR (no change on FLAIR sequence and presence of infarct on MRI-DWI) if \\> 6 hours or unknown last known well time;\n3. Occlusion of the internal carotid artery, M1 or M2 segment of the middle cerebral artery confirmed by CTA\u002FMRA\u002FDSA;\n4. Baseline ASPECTS score of 0-2 or infarct core volume ≥100ml;\n5. The patient or patient's representative signs a written informed consent form.\n\nExclusion Criteria:\n\n1. CT or MR evidence of hemorrhage;\n2. Evidence of mass effect with ventricular effacement, midline shift or herniation on baseline imaging;\n3. Vessel tortuosity where it is expected that the thrombectomy device will not be able to reach the occlusion site or result in unstable access;\n4. History of bleeding disorders, severe heart, liver or kidney disease, or sepsis;\n5. Currently participating in another investigational drug study;\n6. Any terminal illness with life expectancy less than 6 months.",{"count":102,"type":22},286,[104],"NA","The role of endovascular thrombectomy in patients with extra-large ischemic burden is still unclear. The XL STROKE-2 randomized trial is aiming to investigate the efficacy and safety of mechanical thrombectomy in acute extra-large ischemic stroke patients with large vessel occlusion.",[107],"Stroke, Acute Ischemic","2025-12-18",{"date":110,"type":34},"2025-12-26",{"date":112,"type":34},"2024-06-16",{"date":114,"type":22},"2027-01-31",{"name":40,"class":41},2,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100584163","phase-2-efgartigimod-for-the-treatment-of-guillain-barr-syndrome-100584163","NCT06885762","Efgartigimod for the Treatment of Guillain-Barré Syndrome","Safety and Efficacy of Efgartigimod in Guillain-Barré Syndrome","Inclusion Criteria:\n\n1. Aged 18 years or older;\n2. Meet the diagnostic criteria as specified in the \\*European Guidelines for the Diagnosis and Treatment of Guillain-Barré Syndrome 2023 Edition\\*;\n3. Onset of GBS symptoms within 2 weeks prior to enrollment;\n4. GBS-DS score of 3-5;\n5. Written informed consent obtained.\n\nExclusion Criteria:\n\n1. Patients with GBS symptoms for more than 2 weeks;\n2. Known hypersensitivity of the study subject to any component of the investigational drug or any other anti-neonatal Fc receptor (FcRn) agent;\n3. Any uncontrolled active infection or severe infection within 8 weeks prior to screening;\n4. Patients with other autoimmune diseases, such as Sjögren's syndrome, systemic lupus erythematosus, neuromyelitis optica, myasthenia gravis, multiple sclerosis, etc., requiring treatment with immunosuppressive agents;\n5. Vaccination within 4 weeks prior to screening or planned vaccination during the study period;\n6. Pregnant or breastfeeding, or planning to become pregnant during the study period, or women of childbearing potential not using effective contraception;\n7. Currently participating in another clinical trial of similar investigational agents (FcRn antagonists);\n8. Use of the investigational drug within 3 months prior to screening or within five half-lives of the drug (whichever is longer);\n9. Patients with a history of malignancy, including malignant thymoma, myeloproliferative or lymphoproliferative disorders, unless considered cured by adequate treatment and without evidence of recurrence for ≥3 years prior to screening. Patients with completely resected non-melanoma skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) or carcinoma in situ of the cervix are eligible at any time;\n10. Patients with clinical evidence of other significant severe diseases or who have recently undergone major surgery, which may confound study results or place the patient at undue risk. Patients with severe renal\u002Fhepatic impairment may be included.",{"count":21,"type":22},[26,52],"The goal of this clinical trial is to evaluating the efficacy and safety of efgartigimod in the treatment of Guillain-Barré Syndrome and exploring the immunological mechanisms of efgartigimod therapy in Guillain-Barré Syndrome. The main questions it aims to answer are:\n\nWill efgartigimod improve the symptoms of participants? What medical problems do participants have when using efgartigimod?\n\nParticipants will:\n\nOn day 1 and day 5 of the treatment period, drug A was administered intravenously.\n\nKeep a diary of their symptoms",[128],"Guillain-Barre Syndrome (GBS)","2025-03-13",{"date":131,"type":34},"2025-03-20",{"date":133,"type":22},"2025-04-13",{"date":135,"type":22},"2026-12-31",{"name":40,"class":41},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100582085","phase-3-ripertamab-for-the-treatment-of-chronic-inflammatory-demyelinating-polyneuropathy-100582085","NCT06858722","Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy","Safety and Efficacy of Ripertamab in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (RIPERT-CIDP): a Randomised, Double-blind, Multicentre, Placebo-controlled Phase 3 Trial","RIPERT-CIDP","Inclusion Criteria:\n\n1. Able to understand the requirements of the trial, provide written informed consent (including consent to use and disclose health information related to the study), and willing and able to comply with the trial protocol procedures (including required trial visits);\n2. Aged 18 years or older at the time of signing the informed consent form;\n3. Diagnosed with definite CIDP according to the 2021 EFNS\u002FPNS criteria;\n4. CIDP Disease Activity Status (CDAS) score of ≥2 at screening;\n5. INCAT score of at least 2 at initial screening;\n6. Meet one of the following conditions: currently receiving oral corticosteroid therapy (equivalent to prednisone\u002F prednisolone ≤10 mg\u002Fday), and\u002For intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg), but willing to discontinue this treatment before screening; or untreated: no prior treatment; or discontinued corticosteroids and\u002For IVIg or SCIg at least 6 months before screening;\n7. Women of childbearing potential with a negative pregnancy test at screening and a negative urine pregnancy test at baseline;\n8. Women of childbearing potential must use a highly effective contraceptive method (failure rate less than 1% per year) from screening until 90 days after the last administration of the investigational medicinal product (IMP);\n9. Men who are not surgically sterile and have partners of childbearing potential must use condoms, and their partners must use a highly effective contraceptive method from screening until 90 days after the last administration of the IMP (failure rate less than 1% per year). Men who are surgically sterile (documented azoospermia following vasectomy) may be included. In addition, men must not donate sperm from screening until 90 days after the last administration of the IMP.\n\nExclusion Criteria:\n\n1. Pure sensory atypical CIDP (defined by EFNS\u002FPNS criteria);\n2. Polyneuropathy due to other causes, including but not limited to: multifocal motor neuropathy, monoclonal gammopathy of undetermined significance caused by anti-myelin-associated glycoprotein immunoglobulin M antibodies, hereditary demyelinating neuropathy, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes syndrome, lumbosacral radiculoplexus neuropathy, polyneuropathy most likely caused by diabetes, polyneuropathy most likely caused by systemic disease, polyneuropathy caused by drugs or toxins;\n3. Any disease that can better explain the patient's symptoms and signs;\n4. History of any myelopathy or evidence of central demyelination;\n5. Current or past (within 12 months before screening) history of alcohol, drug, or substance abuse;\n6. Severe psychiatric disorder (e.g., major depression, psychosis, bipolar disorder), history of suicide attempt, or current suicidal ideation that the investigator believes may pose undue risk to the patient or affect the patient's ability to comply with the trial protocol;\n7. Clinically significant active or chronic uncontrolled bacterial, viral, or fungal infections at screening, including patients with active viral infections detected at screening: active hepatitis B virus (serological tests indicate active \\[acute or chronic\\] infection), active hepatitis C virus (HCV) (HCV-Ab seropositive), human immunodeficiency virus seropositive with acquired immunodeficiency syndrome-defining conditions or CD4 count ≤200 cells\u002Fmm³;\n8. Total immunoglobulin G level \\\u003C6 g\u002FL at screening;\n9. Received the following treatments: within 1 month before screening (or five half-lives of the drug, whichever is longer): plasmapheresis or immunoadsorption, or any other investigational product; within 6 months before screening: any anti-CD20 monoclonal antibody or other biologic (e.g., rituximab), alemtuzumab, any other monoclonal antibody, cyclophosphamide, interferon, tumor necrosis factor-α inhibitor, fingolimod, methotrexate, azathioprine, mycophenolate mofetil, any other immunomodulatory or immunosuppressive drug, and oral daily corticosteroids \\>10 mg\u002Fday (patients using IVIg, SCIg, corticosteroid pulse therapy, and oral daily corticosteroids ≤10 mg\u002Fday may be included);\n10. Pregnant and breastfeeding women, and those who plan to become pregnant during the trial or within 90 days after the last dose;\n11. Any other known autoimmune disease that the investigator believes may interfere with the accurate assessment of CIDP clinical symptoms;\n12. Received live attenuated vaccines within 28 days before screening (patients who received inactivated, subunit, polysaccharide, or conjugate vaccines at any time before screening are not considered exclusion criteria);\n13. History of malignancy, unless the patient has been free of recurrence for ≥3 years after adequate treatment before the first dose. Patients with the following cancers may be included at any time: adequately treated basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, ductal carcinoma in situ of the breast, or prostate cancer (tumor, node, and metastasis stage T1a or T1b);\n14. Patients who have previously participated in a Ripertamab trial and received ≥1 dose of Ripertamab;\n15. Patients with a history of known hypersensitivity to any component of Ripertamab;\n16. Any other significant severe disease, or recent major surgery or planned major surgery, or any other reason that may confound trial results or pose undue risk to the patient.",{"count":146,"type":22},175,[52],"The goal of this clinical trial is to learn if ripertamab works to treat chronic inflammatory demyelinating polyneuropathy. It will also learn about the safety of ripertamab. The main questions it aims to answer are:\n\nDoes ripertamab reduce the risk of recurrence in patients? What medical problems do participants have when taking ripertamab? Researchers will compare ripertamab to a placebo (a look-alike substance that contains no drug) to see if ripertamab works to treat chronic inflammatory demyelinating polyneuropathy.\n\nParticipants will:\n\nA single intravenous infusion of drug ABC or placebo. Visit the clinic for checkups and tests during W1, W2, W4, W8, W12 Keep a diary of their symptoms and the number of times they undergo rescue therapy",[150],"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","2025-02-27",{"date":153,"type":34},"2025-03-05",{"date":155,"type":22},"2025-03-15",{"date":157,"type":22},"2027-12-31",{"name":40,"class":41},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":4},"100568665","phase-2-blinatumomab-in-refractory-myasthenia-gravis-blina-mg-100568665","NCT06684184","Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG)","Safety and Efficacy of Blinatumomab in Refractory Myasthenia Gravis","BLINA-MG","Inclusion Criteria:\n\n* 18 years old ≤ Age ≤ 75 years old\n* patients with a Myasthenia Gravis Activities of Daily Living (MG-ADL) scale score of 6 or higher, and an ocular muscle score constituting less than 50% of the total score\n* after receiving an adequate course of at least two conventional immunotherapeutic drugs (including both steroidal and non-steroidal immunosuppressants), the Post-Intervention Status (PIS) remains unchanged or worsens; or after receiving an adequate course of at least two conventional immunotherapeutic drugs, the PIS improves, but the MG-ADL score is still ≥6 points and persists for at least half a year; or after receiving an adequate course of at least two conventional immunotherapeutic drugs, the PIS is in remission or improvement, yet during the regular tapering of immunotherapeutic drugs, there are still at least two annual exacerbations of disease symptoms (MG-ADL score ≥6 points); or after the occurrence of a crisis, despite multiple immunotherapies such as intravenous immunoglobulin, plasmapheresis, and high-dose intravenous methylprednisolone, and active infection control, the patient still cannot be weaned off the ventilator due to MG-induced respiratory muscle weakness for more than 14 days\n* positive for anti-AChR, and\u002For anti-MuSK, and\u002For anti-LRP4 antibodies.\n* patient or their legal representative signs an informed consent form in writing\n\nExclusion Criteria:\n\n* pregnant or lactating women\n* individuals with an allergy to Blinatumomab\n* individuals who have undergone thymectomy within the 12 months prior to baseline or who are planning to have a thymectomy during the 12-week study period\n* individuals who have received biologic agents targeting CD19 or CD20 within 6 months prior to baseline are eligible for enrollment (subjects with CD19 or CD20 positive B cell counts above the lower limit of normal are allowed to participate)\n* within the 3 months prior to baseline, use of Ecuzumab and Tocilizumab\n* received intravenous immunoglobulin or plasma exchange therapy within 4 weeks prior to baseline\n* currently participating in other clinical studies",{"count":168,"type":22},10,[26,52],"The goal of this clinical trial is to evaluating the efficacy and safety of Blinatumomab in the treatment of refractory myasthenia gravis and exploring the immunological mechanisms of Blinatumomab therapy in refractory myasthenia gravis. The main questions it aims to answer are:\n\nWill Blinatumomab improve the symptoms of participants? What medical problems do participants have when using Blinatumomab?\n\nParticipants will:\n\nContinuous intravenous infusion of Blinatumomab for 5 days, pause for one week, and continue continuous intravenous infusion for 5 days Visit the clinic once every 1 month for checkups and tests Keep a diary of their symptoms",[172],"Myasthaenia Gravis","2024-11-10",{"date":175,"type":34},"2024-11-12",{"date":177,"type":22},"2024-11-30",{"date":179,"type":22},"2026-06-30",{"name":40,"class":41},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100544757","phase-2-tirofiban-for-successful-endovascular-stroke-thrombectomy-100544757","NCT06373042","Tirofiban for Successful Endovascular Stroke Thrombectomy","Efficacy and Safety of Tirofiban Versus Placebo After Successful Reperfusion With Endovascular Thrombectomy in Acute Ischemic Stroke Patients With Anterior Circulation Large Vessel Occlusion: a Multicenter, Double-Blind, Randomized Clinical Trial","ADJUVANT-2","Inclusion Criteria:\n\n* Clinical inclusion criteria\n\n  1. Aged 18 years or older;\n  2. Acute ischemic stroke within 24 hours from last known well to randomization;\n  3. NIHSS score ≥6 and \\\u003C30 points at baseline;\n  4. Written informed consent is obtained from patients and\u002For their legal representatives.\n* Imaging inclusion criteria\n\n  1. CTA\u002FMRA\u002FDSA showed occlusion of the internal carotid artery, middle cerebral artery M1 or M2 segment;\n  2. For patients within 6 hours from last known well to randomization, ASPECTS 3-10 or infarct volume ≤100ml; 6-24 hours, ASPECTS 6-10 or infarct volume ≤70ml or DWI-FLAIR mismatch;\n  3. Treated with endovascular thrombectomy and achieved successful reperfusion (defined as eTICI grade 2b50 or higher).\n\nExclusion Criteria:\n\n1. Cardiogenic embolism;\n2. Patient receive tirofiban for angioplasty\u002Fstenting prior to randomization;\n3. Intracranial hemorrhage confirmed by flat panel CT on angiography machine prior to randomization;\n4. Patients who are on prior anticoagulant therapy, e.g. for deep venous thrombosis or pulmonary embolism or mechanical heart valve;\n5. Routine blood test platelet count less than 100×10⁹\u002FL;\n6. Renal insufficiency, glomerular filtration rate \\\u003C 60 mL\u002Fmin;\n7. Pregnant or lactating women;\n8. Allergy to tirofiban, contrast agent, nickel, titanium or its alloys;\n9. History of neurological or psychiatric illness that precludes the assessment of neurological function;\n10. History of bleeding disorder, severe heart, liver or kidney disease, or sepsis;\n11. Any terminal illness with life expectancy less than 6 months;\n12. Participating in other treatment clinical trials.",{"count":190,"type":22},712,[26,52],"Up to 50% of acute ischemic stroke patients with large vessel occlusion failed to achieve functional independence even after successful reperfusion therapy, a phenomenon that is referred to as \"futile recanalization\". The mechanism of futile recanalization is complex, and some studies have shown that it may be related to factors such as tissue no reflow, reocclusion, poor status of collateral circulation, hemorrhagic transformation, impaired cerebrovascular autonomic regulation, and low perfusion volume. Several studies suggested that maximizing the improvement of cerebral reperfusion is still the primary goal of acute large vessel occlusive stroke. Structural and functional alterations in the microvascular system may be a major obstacle to reperfusion. In animal models of cerebral ischemia, downstream microvascular thrombosis may occur in the early stage of cerebral ischemia and before vascular recanalization, which is the main factor leading to incomplete reperfusion and affecting the efficacy of endovascular thrombectomy.\n\nMechanical thrombectomy mainly addressed the occluded large arteries, and does not consider the distal arteries. However, the recanalization of occluded large arteries does not necessarily translate into successful reperfusion of the ischemic tissue supplied by the distal capillaries. Even with complete recanalization, impaired microcirculatory reperfusion may lead to poor clinical outcomes. Therefore, we speculate that at the end of endovascular thrombectomy, microthrombi remain present in the microcirculation of brain tissue in patients with complete or near-complete cerebral angiography, and that microthrombi is more likely to be dissolved than thrombus more proximal to the heart. Therefore, intra-arterial administration of pharmaceutical, such as tirofiban, may be the only possible option to ensure complete reperfusion of ischemic tissue. Tirofiban is a platelet glycoprotein IIb\u002FIIIa receptor antagonist, which has been widely used in acute coronary syndrome, and its role in acute ischemic stroke has attracted more and more attention from stroke experts. Previous studies have suggested that tirofiban can further increase the incidence of successful recanalization, while reducing the reocclusion rate.\n\nWhether early administration of intraarterial and intravenous tirofiban can further improve the clinical outcomes of patients with large vessel occlusive stroke after successful mechanical thrombectomy remains unclear.",[107],"2024-05-13",{"date":196,"type":34},"2024-05-16",{"date":198,"type":22},"2024-07-31",{"date":200,"type":22},"2026-10-31",{"name":40,"class":41},{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":23,"phases":213,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":92},"100507755","dti-guided-minimally-invasive-hematoma-evacuation-for-intracerebral-hemorrhage-100507755","NCT05891509","DTI-guided Minimally Invasive Hematoma Evacuation for Intracerebral Hemorrhage","Efficacy and Safety of DTI-guided Minimally Invasive Hematoma Evacuation Versus Best Medical Therapy for Acute Spontaneous Intracerebral Hemorrhage: a Randomized Controlled Trial","GLAMOR","Inclusion Criteria:\n\n1. Age 18-80 years old;\n2. Intracerebral hemorrhage in the basal ganglia was diagnosed by CT examination;\n3. The amount of bleeding is 20-40ml, and the midline structure is displaced horizontally by \\\u003C 3mm in the pineal gland;\n4. The degree of integrity and continuity of the corticospinal tract on the lesion side of magnetic resonance diffusion tensor imaging was graded as grade 2\\~4;\n5. The time from onset to randomization is within 24 hours;\n6. GCS score ≥ 4 points at randomization;\n7. Muscle strength level 3 in the affected limb;\n8. Written informed consent are provided by the patients or their legal representatives.\n\nExclusion Criteria:\n\n1. Bleeding in other parts (e.g., bleeding in subtentorial areas such as thalamus, brainstem or cerebellum);\n2. Bleeding caused by other causes (such as aneurysm, arteriovenous malformation, brain trauma, brain tumor, bleeding transformation of large cerebral infarction, bleeding caused by β amyloidosis, bleeding caused by coagulation dysfunction) or combined with aneurysm, arteriovenous malformation, brain trauma, brain tumor, large-scale cerebral infarction, β amyloidosis, severe coagulation dysfunction;\n3. Multiple intracranial hemorrhage;\n4. Patients with ventricular hemorrhage or ICH rupture into the ventricles should consider the need for ventricular drainage;\n5. Any history of brain parenchymal or other intracranial subarachnoid, subdural or epidural hemorrhage and surgical history in the past 30 days;\n6. Myocardial infarction within the past 30 days;\n7. Previous history of bleeding, such as gastrointestinal bleeding, genitourinary bleeding, respiratory bleeding that has not been completely controlled;\n8. Hemoglobin \\\u003C 100g\u002FL, hematocrit \\\u003C25%, platelet count \\\u003C 100\\*109\u002FL;\n9. Receiving anticoagulant drugs such as warfarin, dabigatran or rivaroxaban within 1 week prior to enrollment, with an INR \\> 1.4;\n10. Long-term anticoagulation and antiplatelet therapy are expected to be required;\n11. Allergy to alpeplase, urokinase or surgery-related drugs and instruments;\n12. Pregnant or lactating women;\n13. Known high risk of embolism, including patients with mechanical heart valves implanted in the body, history of left heart thrombosis, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. Atrial fibrillation without mitral stenosis is appropriate;\n14. hypertension (systolic blood pressure is still greater than 180mmHg) that cannot be effectively controlled by aggressive antihypertensive therapy before randomization;\n15. Life expectancy \\\u003C 12 months in the advanced stage of any disease;\n16. Participating in other interventional clinical studies.","80 Years",{"count":212,"type":22},100,[104],"Intracerebral hemorrhage (ICH) is a devastating disease with high early mortality, unfavorable neurological outcomes, and high cost of care. To date, the role of DTI-guided minimally invasive hematoma evacuation in ICH is still uncertain.\n\nThe investigators will conduct a multicenter randomized controlled trial, as well as a concurrent prospective observational study including all ICH patients who decline participation in the trial and will therefore receive minimally invasive hematoma evacuation or best medical therapy and consent to be followed up. All participants will be followed up at the same time using the same outcomes measures. The primary outcome will be collected by a blinded assessor.",[216],"Stroke Hemorrhagic",[218,219,220,221],"Minimally Invasive Hematoma Evacuation","Intracerebral Hemorrhage","Randomized Controlled Trial","Magnetic Resonance Imaging","2023-09-08",{"date":224,"type":34},"2023-09-13",{"date":226,"type":34},"2023-08-03",{"date":228,"type":22},"2027-08-31",{"name":40,"class":41},""]